---
document_datetime: 2025-12-02 05:32:41
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/memantine-ratiopharm.html
document_name: memantine-ratiopharm.html
version: success
processing_time: 0.1283486
conversion_datetime: 2025-12-24 04:13:41.145066
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Memantine ratiopharm

[RSS](/en/individual-human-medicine.xml/66848)

##### Authorised

This medicine is authorised for use in the European Union

memantine Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Memantine ratiopharm](#more-information-on-memantine-ratiopharm-1450)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Memantine ratiopharm. It explains how the European Medicines Agency assessed the medicine to recommend its authorisation in the European Union and its conditions of use. It is not intended to provide practical advice on how to use Memantine ratiopharm.

For practical information about using Memantine ratiopharm, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Memantine ratiopharm and what is it used for?

Memantine ratiopharm is a medicine that contains the active substance memantine hydrochloride. It is used to treat patients with moderate to severe Alzheimer's disease. Alzheimer's disease is a type of dementia (a brain disorder) that gradually affects memory, intellectual ability and behaviour.

Memantine ratiopharm is a 'generic medicine'. This means that Memantine ratiopharm is similar to a 'reference medicine' already authorised in the European Union (EU) called Ebixa.

## How is Memantine ratiopharm used?

Memantine ratiopharm is available as tablets (5 mg, 10 mg, 15 mg and 20 mg) and can only be obtained with a prescription.

Treatment should be started and supervised by a doctor who has experience in the diagnosis and treatment of Alzheimer's disease. Treatment should only be started if a caregiver is available who will regularly monitor the use of Memantine ratiopharm by the patient.

Memantine ratiopharm should be given once a day at the same time every day. To prevent side effects, the dose of Memantine ratiopharm is gradually increased over the first three weeks of treatment: during the first week, the dose is 5 mg; in the second week, it is 10 mg; and during the third week, it is 15 mg. From week four onwards, the recommended maintenance dose is 20 mg once a day. The tolerance and dose should be assessed within three months after starting treatment, and from then on the benefits of continuing treatment with Memantine ratiopharm should be re-assessed on a regular basis. The dose may need to be reduced in patients who have moderate or severe problems with their kidneys.

For more information, see the package leaflet.

## How does Memantine ratiopharm work?

The active substance in Memantine ratiopharm, memantine hydrochloride, is an antidementia medicine. The cause of Alzheimer's disease is unknown, but memory loss in the disease is believed to be due to a disturbance of message signals in the brain.

Memantine works by blocking special types of receptor called N-methyl-D-aspartate (NMDA) receptors, to which the neurotransmitter glutamate normally attaches. Neurotransmitters are chemicals in the nervous system that allow nerve cells to communicate with one another. Changes in the way glutamate transmits signals within the brain have been linked to the memory loss seen in Alzheimer's disease. In addition, overstimulation of the NMDA receptors can result in cell damage or death. By blocking NMDA receptors, memantine improves the transmission of signals in the brain and reduces the symptoms of Alzheimer's disease.

## How has Memantine ratiopharm been studied?

Because Memantine ratiopharm is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Ebixa. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

## What are the benefits and risks of Memantine ratiopharm?

Because Memantine ratiopharm is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Memantine ratiopharm approved?

The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Memantine ratiopharm has been shown to have comparable quality and to be bioequivalent to Ebixa. Therefore, the CHMP's view was that, as for Ebixa, the benefit outweighs the identified risk. The Committee recommended that Memantine ratiopharm be approved for use in the EU.

## What measures are being taken to ensure the safe and effective use of Memantine ratiopharm?

Safety information has been included in the summary of product characteristics and the package leaflet for Memantine ratiopharm, including the appropriate precautions to be followed by healthcare professionals and patients.

## Other information about Memantine ratiopharm

The European Commission granted a marketing authorisation valid throughout the European Union for Memantine ratiopharm on 13 June 2013.

For more information about treatment with Memantine ratiopharm, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Memantine ratiopharm : EPAR - Summary for the public

Reference Number: EMEA/H/C/002671

English (EN) (67.97 KB - PDF)

**First published:** 20/06/2013

**Last updated:** 20/06/2013

[View](/en/documents/overview/memantine-ratiopharm-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-118)

български (BG) (117.8 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/bg/documents/overview/memantine-ratiopharm-epar-summary-public_bg.pdf)

español (ES) (90.65 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/es/documents/overview/memantine-ratiopharm-epar-summary-public_es.pdf)

čeština (CS) (115.75 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/cs/documents/overview/memantine-ratiopharm-epar-summary-public_cs.pdf)

dansk (DA) (89.62 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/da/documents/overview/memantine-ratiopharm-epar-summary-public_da.pdf)

Deutsch (DE) (69.02 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/de/documents/overview/memantine-ratiopharm-epar-summary-public_de.pdf)

eesti keel (ET) (89.32 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/et/documents/overview/memantine-ratiopharm-epar-summary-public_et.pdf)

ελληνικά (EL) (118.09 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/el/documents/overview/memantine-ratiopharm-epar-summary-public_el.pdf)

français (FR) (91.21 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/fr/documents/overview/memantine-ratiopharm-epar-summary-public_fr.pdf)

italiano (IT) (90.02 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/it/documents/overview/memantine-ratiopharm-epar-summary-public_it.pdf)

latviešu valoda (LV) (89.04 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/lv/documents/overview/memantine-ratiopharm-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (113.63 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/lt/documents/overview/memantine-ratiopharm-epar-summary-public_lt.pdf)

magyar (HU) (110.61 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/hu/documents/overview/memantine-ratiopharm-epar-summary-public_hu.pdf)

Malti (MT) (93.69 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/mt/documents/overview/memantine-ratiopharm-epar-summary-public_mt.pdf)

Nederlands (NL) (90.61 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/nl/documents/overview/memantine-ratiopharm-epar-summary-public_nl.pdf)

polski (PL) (115.97 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/pl/documents/overview/memantine-ratiopharm-epar-summary-public_pl.pdf)

português (PT) (90.71 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/pt/documents/overview/memantine-ratiopharm-epar-summary-public_pt.pdf)

română (RO) (89.1 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/ro/documents/overview/memantine-ratiopharm-epar-summary-public_ro.pdf)

slovenčina (SK) (115.01 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/sk/documents/overview/memantine-ratiopharm-epar-summary-public_sk.pdf)

slovenščina (SL) (108.49 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/sl/documents/overview/memantine-ratiopharm-epar-summary-public_sl.pdf)

Suomi (FI) (90.34 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/fi/documents/overview/memantine-ratiopharm-epar-summary-public_fi.pdf)

svenska (SV) (89.93 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/sv/documents/overview/memantine-ratiopharm-epar-summary-public_sv.pdf)

## Product information

Memantine ratiopharm : EPAR - Product Information

English (EN) (510.63 KB - PDF)

**First published:** 20/06/2013

**Last updated:** 30/06/2022

[View](/en/documents/product-information/memantine-ratiopharm-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-1)

български (BG) (611.13 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

30/06/2022

[View](/bg/documents/product-information/memantine-ratiopharm-epar-product-information_bg.pdf)

español (ES) (513.26 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

30/06/2022

[View](/es/documents/product-information/memantine-ratiopharm-epar-product-information_es.pdf)

čeština (CS) (633.74 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

30/06/2022

[View](/cs/documents/product-information/memantine-ratiopharm-epar-product-information_cs.pdf)

dansk (DA) (512.71 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

30/06/2022

[View](/da/documents/product-information/memantine-ratiopharm-epar-product-information_da.pdf)

Deutsch (DE) (552.2 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

30/06/2022

[View](/de/documents/product-information/memantine-ratiopharm-epar-product-information_de.pdf)

eesti keel (ET) (512.67 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

30/06/2022

[View](/et/documents/product-information/memantine-ratiopharm-epar-product-information_et.pdf)

ελληνικά (EL) (633.07 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

30/06/2022

[View](/el/documents/product-information/memantine-ratiopharm-epar-product-information_el.pdf)

français (FR) (532.16 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

30/06/2022

[View](/fr/documents/product-information/memantine-ratiopharm-epar-product-information_fr.pdf)

hrvatski (HR) (598.24 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

30/06/2022

[View](/hr/documents/product-information/memantine-ratiopharm-epar-product-information_hr.pdf)

íslenska (IS) (516.03 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

30/06/2022

[View](/is/documents/product-information/memantine-ratiopharm-epar-product-information_is.pdf)

italiano (IT) (526.59 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

30/06/2022

[View](/it/documents/product-information/memantine-ratiopharm-epar-product-information_it.pdf)

latviešu valoda (LV) (585.27 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

30/06/2022

[View](/lv/documents/product-information/memantine-ratiopharm-epar-product-information_lv.pdf)

lietuvių kalba (LT) (577.29 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

30/06/2022

[View](/lt/documents/product-information/memantine-ratiopharm-epar-product-information_lt.pdf)

magyar (HU) (615.83 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

30/06/2022

[View](/hu/documents/product-information/memantine-ratiopharm-epar-product-information_hu.pdf)

Malti (MT) (637.55 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

30/06/2022

[View](/mt/documents/product-information/memantine-ratiopharm-epar-product-information_mt.pdf)

Nederlands (NL) (521.05 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

30/06/2022

[View](/nl/documents/product-information/memantine-ratiopharm-epar-product-information_nl.pdf)

norsk (NO) (539.97 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

30/06/2022

[View](/no/documents/product-information/memantine-ratiopharm-epar-product-information_no.pdf)

polski (PL) (599.62 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

30/06/2022

[View](/pl/documents/product-information/memantine-ratiopharm-epar-product-information_pl.pdf)

português (PT) (538.83 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

30/06/2022

[View](/pt/documents/product-information/memantine-ratiopharm-epar-product-information_pt.pdf)

română (RO) (575 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

30/06/2022

[View](/ro/documents/product-information/memantine-ratiopharm-epar-product-information_ro.pdf)

slovenčina (SK) (613.4 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

30/06/2022

[View](/sk/documents/product-information/memantine-ratiopharm-epar-product-information_sk.pdf)

slovenščina (SL) (579.56 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

30/06/2022

[View](/sl/documents/product-information/memantine-ratiopharm-epar-product-information_sl.pdf)

Suomi (FI) (520.33 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

30/06/2022

[View](/fi/documents/product-information/memantine-ratiopharm-epar-product-information_fi.pdf)

svenska (SV) (549.11 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

30/06/2022

[View](/sv/documents/product-information/memantine-ratiopharm-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0023 03/06/2022

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Memantine ratiopharm : EPAR - All Authorised presentations

English (EN) (29.88 KB - PDF)

**First published:** 20/06/2013

**Last updated:** 20/06/2013

[View](/en/documents/all-authorised-presentations/memantine-ratiopharm-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-945)

български (BG) (51.34 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/bg/documents/all-authorised-presentations/memantine-ratiopharm-epar-all-authorised-presentations_bg.pdf)

español (ES) (26.36 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/es/documents/all-authorised-presentations/memantine-ratiopharm-epar-all-authorised-presentations_es.pdf)

čeština (CS) (37.2 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/cs/documents/all-authorised-presentations/memantine-ratiopharm-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (26.69 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/da/documents/all-authorised-presentations/memantine-ratiopharm-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (26.79 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/de/documents/all-authorised-presentations/memantine-ratiopharm-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (29.83 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/et/documents/all-authorised-presentations/memantine-ratiopharm-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (49.72 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/el/documents/all-authorised-presentations/memantine-ratiopharm-epar-all-authorised-presentations_el.pdf)

français (FR) (29.42 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/fr/documents/all-authorised-presentations/memantine-ratiopharm-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (78.75 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/hr/documents/all-authorised-presentations/memantine-ratiopharm-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (26.73 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/is/documents/all-authorised-presentations/memantine-ratiopharm-epar-all-authorised-presentations_is.pdf)

italiano (IT) (51.54 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/it/documents/all-authorised-presentations/memantine-ratiopharm-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (43.36 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/lv/documents/all-authorised-presentations/memantine-ratiopharm-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (47.1 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/lt/documents/all-authorised-presentations/memantine-ratiopharm-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (41.85 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/hu/documents/all-authorised-presentations/memantine-ratiopharm-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (40.34 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/mt/documents/all-authorised-presentations/memantine-ratiopharm-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (29.51 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/nl/documents/all-authorised-presentations/memantine-ratiopharm-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (29.67 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/no/documents/all-authorised-presentations/memantine-ratiopharm-epar-all-authorised-presentations_no.pdf)

polski (PL) (37.79 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/pl/documents/all-authorised-presentations/memantine-ratiopharm-epar-all-authorised-presentations_pl.pdf)

português (PT) (29.62 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/pt/documents/all-authorised-presentations/memantine-ratiopharm-epar-all-authorised-presentations_pt.pdf)

română (RO) (41.76 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/ro/documents/all-authorised-presentations/memantine-ratiopharm-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (68.14 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/sk/documents/all-authorised-presentations/memantine-ratiopharm-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (34.58 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/sl/documents/all-authorised-presentations/memantine-ratiopharm-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (29.2 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/fi/documents/all-authorised-presentations/memantine-ratiopharm-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (26.53 KB - PDF)

**First published:**

20/06/2013

**Last updated:**

20/06/2013

[View](/sv/documents/all-authorised-presentations/memantine-ratiopharm-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Memantine ratiopharm Active substance memantine hydrochloride International non-proprietary name (INN) or common name memantine Therapeutic area (MeSH) Alzheimer Disease Anatomical therapeutic chemical (ATC) code N06DX01

### Pharmacotherapeutic group

Psychoanaleptics

### Therapeutic indication

Treatment of patients with moderate to severe Alzheimer's disease

## Authorisation details

EMA product number EMEA/H/C/002671

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Ratiopharm GmbH

Graf-Arco-Str. 3

Marketing authorisation issued 12/06/2013 Revision 8

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Memantine ratiopharm : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (178.94 KB - PDF)

**First published:** 17/09/2014

**Last updated:** 30/06/2022

[View](/en/documents/procedural-steps-after/memantine-ratiopharm-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Memantine ratiopharm : EPAR - Public assessment report

Reference Number: EMA/328117/2013

English (EN) (223.38 KB - PDF)

**First published:** 20/06/2013

**Last updated:** 20/06/2013

[View](/en/documents/assessment-report/memantine-ratiopharm-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Memantine ratiopharm

Adopted

Reference Number: EMA/CHMP/157191/2013

English (EN) (63.51 KB - PDF)

**First published:** 22/03/2013

**Last updated:** 22/03/2013

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-memantine-ratiopharm_en.pdf)

#### More information on Memantine ratiopharm

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 30/06/2022

## Share this page

[Back to top](#main-content)